This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
A new preprint design is coming!
We have improved readability, clarity, accessibility, and opportunities for engagement.
Research
Xiaowu Shi
Huazhong University of Science and Technology Tongji Medical College
Corresponding Author
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Background
Primary disease influenced the prognosis of coronavirus disease 2019 (COVID-19), but the clinical characters of patients accompanied with tumor were few reported.
Methods
We enrolled 528 COVID-19 patients. Date of laboratory tests and outcome were divided to corresponding groups to compare the risk factors of disease severity, progression and survival.
Results
The disease severity at hospitalization, progression rate (51.43% vs 54.42%) and mortality (19.51% vs 11.91%) were equal between tumor and non-tumor group. In both groups, lymphopenia was negatively related to the severity grading (OR = 0.019 and 0.168 separately), NLR was positively correlated with the poor outcome (OR = 1.371 and 1.155 separately), and CRP was relevant to the disease progression and survival (OR = 1.334 and 1.303 separately).
Conclusions
Malignancy history may have no marked effect on the severity and prognosis of COVID-19. Lymphopenia, NLR and CRP levels could be regarded as indicators to determine severe cases, and predict progression and survival.
Keywords
COVID-19, malignancy, laboratory finding, survival, progression
Loading...
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
History
CURRENT STATUS: Posted
Version 1
Posted 20 Jul, 2020
No community comments so far
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Learn more about our company.
A new preprint design is coming!
We have improved readability, clarity, accessibility, and opportunities for engagement.
This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Research
Xiaowu Shi
Huazhong University of Science and Technology Tongji Medical College
Corresponding Author
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
History
CURRENT STATUS: Posted
Version 1
Posted 20 Jul, 2020
No community comments so far
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Background
Primary disease influenced the prognosis of coronavirus disease 2019 (COVID-19), but the clinical characters of patients accompanied with tumor were few reported.
Methods
We enrolled 528 COVID-19 patients. Date of laboratory tests and outcome were divided to corresponding groups to compare the risk factors of disease severity, progression and survival.
Results
The disease severity at hospitalization, progression rate (51.43% vs 54.42%) and mortality (19.51% vs 11.91%) were equal between tumor and non-tumor group. In both groups, lymphopenia was negatively related to the severity grading (OR = 0.019 and 0.168 separately), NLR was positively correlated with the poor outcome (OR = 1.371 and 1.155 separately), and CRP was relevant to the disease progression and survival (OR = 1.334 and 1.303 separately).
Conclusions
Malignancy history may have no marked effect on the severity and prognosis of COVID-19. Lymphopenia, NLR and CRP levels could be regarded as indicators to determine severe cases, and predict progression and survival.
Loading...